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background:  A Fab, MEDI2452, is being developed as an antidote for ticagrelor patients requiring urgent surgery or experiencing major or 
life-threatening bleeding where ticagrelor reversal may be desirable.
methods:  MEDI2452 was isolated and optimized by human antibody phage display. The affinity was measured by KinExA and selectivity 
was determined by competition binding. Potency to reverse ticagrelor or its active metabolite (TAM) mediated inhibition of ADP induced 
platelet aggregation was determined in vitro in human platelet rich plasma. Plasma unbound fraction of ticagrelor was determined in 
parallel by equilibrium dialysis. The speed of onset and the extent of MEDI2452 mediated reversal of anti-platelet effect were determined 
ex vivo after intravenous (i.v.) dosing of ticagrelor. Just after termination of ticagrelor infusion, at an average plasma exposure of 1.4 μΜ, 
mice were given an i.v. bolus of 250 mg/kg MEDI2452. At 5, 30 and 60 min post MEDI2452 administration blood samples were collected for 
ADP-induced whole blood aggregometry and plasma exposure.
Results:  MEDI2452 has an affinity for ticagrelor and TAM of 20 pM with no significant binding to adenosine, ADP, ATP or any structurally 
related compounds. The specificity of MEDI2452 for ticagrelor and TAM was supported by a crystal structure of the Fab-Hapten complex. 
MEDI2452 produced a concentration-dependent reversal of 1 μM ticagrelor and TAM mediated inhibition of platelet aggregation with mean 
IC50 values of 0.64 and 0.78 μM, respectively. The recovery of platelet aggregation occurred in parallel with a reduction in plasma unbound 
ticagrelor with mean IC50 value of 0.49 μM. In mice, ticagrelor treatment inhibited ADP induced aggregation by ≥97%. MEDI2452 reversed 
the aggregation response by 34, 94 and 83% at 5, 30 and 60min, respectively.
conclusion:  MEDI2452 1) Specifically binds to ticagrelor and TAM with high affinity, 2) Concentration dependently neutralizes the plasma 
unbound fraction of ticagrelor and reverses ticagrelor and TAM mediated inhibition of platelet aggregation in vitro and 3) Rapidly and 
effectively reverses platelet aggregation when given to ticagrelor treated mice.
